27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average annual returns of 30%. While Druckenmiller closed the firm in 2010, the George Soros protégé is still investing through his family office, the Duquesne Family Office, making him a great model for investors to follow. Roughly 27.5% of Druckenmiller's portfolio is invested in three under-the-radar artificial intelligence (AI) stocks.Druckenmiller's largest position at the end of the fourth quarter was in the molecular biotech company Natera (NASDAQ: NTRA). Duquesne's position at the end of the fourth quarter amounted to over $564 million.Natera combines cell-free DNA technology with statistical algorithms powered by machine learning to identify diseases and conditions . The company's goal is to provide a personalized form of genetic testing that can inform people of conditions and diseases earlier in their life cycles. Currently, the company focuses on women's health, oncology, and organ health. In women's health, Natera created minimally invasive tests to identify genetic conditions like Down syndrome. In oncology, the company developed a personalized blood DNA test, and in organ health the company makes tests to evaluate for kidney, heart, and lung transplant rejection, as well as tests for chronic kidney disease.Continue reading
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average annual returns of 30%. While Druckenmiller closed the firm in 2010, the George Soros protégé is still investing through his family office, the Duquesne Family Office, making him a great model for investors to follow. Roughly 27.5% of Druckenmiller's portfolio is invested in three under-the-radar artificial intelligence (AI) stocks.
Druckenmiller's largest position at the end of the fourth quarter was in the molecular biotech company Natera (NASDAQ: NTRA). Duquesne's position at the end of the fourth quarter amounted to over $564 million.
Natera combines cell-free DNA technology with statistical algorithms powered by machine learning to identify diseases and conditions . The company's goal is to provide a personalized form of genetic testing that can inform people of conditions and diseases earlier in their life cycles. Currently, the company focuses on women's health, oncology, and organ health. In women's health, Natera created minimally invasive tests to identify genetic conditions like Down syndrome. In oncology, the company developed a personalized blood DNA test, and in organ health the company makes tests to evaluate for kidney, heart, and lung transplant rejection, as well as tests for chronic kidney disease.
